Comparative Pharmacology
Head-to-head clinical analysis: AN SULFUR COLLOID versus SELENOMETHIONINE SE 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AN SULFUR COLLOID versus SELENOMETHIONINE SE 75.
AN-SULFUR COLLOID vs SELENOMETHIONINE SE 75
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium Tc-99m sulfur colloid is a radiopharmaceutical that undergoes phagocytosis by the reticuloendothelial system (RES), primarily in the liver, spleen, and bone marrow. It allows imaging of these organs via gamma camera detection of emitted gamma rays.
Radiopharmaceutical agent: selenium-75 decays by electron capture to arsenic-75 with emission of gamma photons. Used as a tracer for pancreatic imaging due to incorporation into pancreatic enzymes. Localizes in pancreas via protein synthesis.
AN-SULFUR COLLOID (technetium Tc-99m sulfur colloid) is not typically dosed in mg but as a radiopharmaceutical based on radioactivity. For liver/spleen imaging: 1-8 mCi (37-296 MBq) intravenously. For gastric emptying: 0.5-1 mCi (18.5-37 MBq) orally. For sentinel lymph node mapping: 0.4-1 mCi (14.8-37 MBq) subcutaneously or intradermally.
0.185-0.37 MBq (5-10 μCi) intravenously as a single dose for pancreatic imaging.
None Documented
None Documented
The terminal elimination half-life is approximately 2-5 minutes (rapid clearance from blood) for the colloid particles, followed by a slower phase of 2-3 hours for degradation of retained sulfur colloid within macrophages. Clinical context: Used for lymphoscintigraphy and liver-spleen imaging; rapid blood clearance allows imaging shortly after injection.
Terminal half-life is approximately 50-60 days, reflecting slow turnover of selenomethionine incorporated into body proteins (e.g., skeletal muscle, erythrocytes).
Primarily via the reticuloendothelial system (liver, spleen, bone marrow) with minimal renal excretion (<2% unchanged in urine). Fecal excretion accounts for <1%. The colloid is phagocytosed by macrophages and retained in tissues; trace amounts may be excreted in bile.
Primarily renal, with 20-30% excreted unchanged in urine; minor fecal elimination (<5%). The remainder is incorporated into endogenous proteins and long-term tissue stores.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical